Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of S-1 with or without thalidomide in heavily pretreated colorectal cancer
ChiCTR1900022946Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tegafur-gimeracil-oteracil and thalidomide in colorectal cancer (CRC) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Disease control rate. Planned start May 2019; status: not yet recruiting.
02
Drugs
tegafur-gimeracil-oteracilthalidomide
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1900022946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022946.